Filter posts

Fireside Chats with Five CEOs Featured at Day Two of the BIO CEO & Investor Conference

Fireside Chat with John F. Milligan, PhD, President & COO, Gilead Sciences The first fireside …

Session Recap: “Trust Your Gut” – Therapeutic Opportunities from the Microbiome

Tuesday at the BIO CEO & Investor Conference kicked off with a Therapeutic Workshop titled, …

Ten Years of Therapeutic Venture Capital

What therapeutic areas have received the most funding in private drug companies over the last …

Session Recap: Digital Health—Early Successes for Investors and Biotech R&D Productivity

Digital health has the potential to improve the life science industry by combining traditional and …

Producing "21st Century Cures" - 2015 U.S. Legislative Outlook with Chairman Upton and Rep. DeGette

BIO President & CEO Jim Greenwood today sat down with Energy & Commerce Committee Chairman …

BIO CEO & Investor Conference Kicks Off in NYC

The 17th Annual BIO CEO & Investor Conference opened today with a record number of partnering …

Getting Ahead of Ebola and Other Infectious Threats—Overturning Assumptions

Ebola was one of the biggest stories of 2014 (with Ebola fighters named the TIME …

How Industry Rates Interactions with the FDA

Kicking off day one of the BIO CEO & Investor Conference in New York City, …

Patients Remain the Focus for the Future of Personalizing Oncology

The 17th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria in New …

Dow Jones VentureWire: BIO Report on Venture Funding for Therapeutic Innovation

Today, Brian Gormley’s story – Biotech VCs Shift Away From Chronic Diseases, Report Says – …